QTERN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Estonia, Finland, Ireland, Lithuania, Poland, Romania, Turkey, UK.

Active ingredients

The drug QTERN contains a combination of these active pharmaceutical ingredients (APIs):

1	Saxagliptin UNII Z8J84YIX6L - SAXAGLIPTIN HYDROCHLORIDE
	Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor. Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
	Read more about Saxagliptin
2	Dapagliflozin UNII 887K2391VH - DAPAGLIFLOZIN PROPANEDIOL
	Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion.
	Read more about Dapagliflozin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QTERN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BD21	Saxagliptin and dapagliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BD Combinations of oral blood glucose lowering drugs
Discover more medicines within A10BD21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11286B, 11305B
BR	Câmara de Regulação do Mercado de Medicamentos	502320030033807, 502320030033907
EE	Ravimiamet	1725511, 1725522, 1725533, 1725544
FI	Lääkealan turvallisuus- ja kehittämiskeskus	026471, 504230
GB	Medicines & Healthcare Products Regulatory Agency	336824
LT	Valstybinė vaistų kontrolės tarnyba	1080763, 1080764, 1080765, 1080766
PL	Rejestru Produktów Leczniczych	100375292
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63069001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699786092884, 8699786092891
US	FDA, National Drug Code	0310-6770, 0310-6780